DAFNA Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

DAFNA Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$546K	Hold	111,859	–	–	0.1%	76
2026 Q1	$535K	Sell	111,859 -15,000	-12%	-$82.3K	0.12%	77
2025 Q4	$685K	Hold	126,859	–	–	0.16%	65
2025 Q3	$620K	Sell	126,859 -173,593	-58%	-$920K	0.15%	66
2025 Q2	$1.41M	Sell	300,452 -4,300	-1%	-$18K	0.39%	46
2025 Q1	$1.11M	Buy	304,752 +118,035	+63%	+$538K	0.32%	54
2024 Q4	$881K	Buy	186,717 +149,053	+396%	+$1.09M	0.22%	63
2024 Q3	$351K	Sell	37,664 -4,186	-10%	-$30.3K	0.08%	76
2024 Q2	$241K	Buy	+41,850	New	+$249K	0.06%	78

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

DAFNA Capital Management's FHTX Position: Q2 2026 in Review

DAFNA Capital Management held its Foghorn Therapeutics (FHTX) position steady in Q2 2026 at 111,859 shares worth $546K. The position accounts for 0.1% of the portfolio, ranked #76.

DAFNA Capital Management first reported a position in FHTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.41M in Q2 2025. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

DAFNA Capital Management held 111,859 shares of Foghorn Therapeutics worth $546K as of Q2 2026.
DAFNA Capital Management left its Foghorn Therapeutics share count unchanged in Q2 2026.
Foghorn Therapeutics made up 0.1% of DAFNA Capital Management's portfolio in Q2 2026, its #76 holding.
DAFNA Capital Management first reported a position in Foghorn Therapeutics in Q2 2024 and has held it in 9 quarters since.
DAFNA Capital Management's Foghorn Therapeutics position peaked at $1.41M in Q2 2025.
103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.